Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562616 | 0.90 | GRM2 (0.63) | CYP3A4GRM2 | |
| SCHEMBL5556974 | 0.90 | CYP3A4 (0.81) | CYP3A4GRM2 | |
| SCHEMBL5558237 | 0.89 | CYP3A4 (0.80) | CYP3A4GRM2 | |
| SCHEMBL5566323 | 0.89 | CYP3A4 (0.71) | CYP3A4GRM2 | |
| SCHEMBL5566701 | 0.88 | GRM2 (0.79) | CYP3A4GRM2 | |
| SCHEMBL5563598 | 0.88 | CYP3A4 (0.77) | CYP3A4GRM2 | |
| SCHEMBL5562835 | 0.88 | CYP3A4 (0.80) | CYP3A4GRM2 | |
| SCHEMBL5557686 | 0.87 | CYP3A4 (1.00) | CYP3A4GRM2 | |
| SCHEMBL5563421 | 0.87 | GRM2 (0.74) | CYP3A4GRM2 | |
| SCHEMBL5562950 | 0.86 | GRM2 (0.67) | CYP3A4GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | CYP3A4 188/4885GRM2 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.